The Pharmaceutical Market: Spain

Date: January 31, 2013
Pages: 93
Price:
US$ 1,295.00
License [?]:
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P0EBB96912BEN
Leaflet:

Download PDF Leaflet

The Pharmaceutical Market: Spain
OVERVIEW OF THE PHARMACEUTICAL MARKET IN SPAIN

The sharp drop in public pharmaceutical expenditure in Spain in the first four months of 2012 serves as a warning for the continuation of a fall in spending on medicines in the remainder of the year. BMI notes that this does not bode well for drugmakers selling their products in Spain as the success of the implemented policies may encourage the enforcement of further cost-containment measures, which, together with the ongoing public hospital debt situation, seriously hampers the country's attractiveness as a location in which to sell drugs, despite its favourable demographic characteristics.

Headline Expenditure Projections

Pharmaceuticals: EUR20.15bn (US$28.00bn) in 2011 to EUR18.34bn (US$23.30bn) in 2012; -9.0% in local currency terms and -16.8% in US dollar terms.

Healthcare: EUR104.99bn (US$145.93bn) in 2011 to EUR105.51bn (US$133.99bn) in 2012; +0.5% in local currency terms and -8.2% in US dollar terms.

Medical devices: EUR4.32bn (US$6.01bn) in 2011 to EUR4.35bn (US$5.52bn) in 2011; +0.7% in local currency terms and -8.0% in US dollar terms.

Risk/Reward Ratings: Pharmaceutical Risk/Reward Ratings (RRRs) for Q412, Spain is ranked eight among the 10 countries surveyed in Western Europe. While Spain offers investors positive factors, such as its large drug market, it also has problems, such as the government's focus on cost containment, low population growth, cumbersome bureaucracy and provincial differences regarding drug regulations and reimbursement.

Competitive Landscape

The Competitive Landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
BMI INDUSTRY VIEW

EXECUTIVE SUMMARY

SWOT

SPAIN PHARMACEUTICALS AND HEALTHCARE INDUSTRY SWOT

POLITICAL

ECONOMIC

BUSINESS ENVIRONMENT

INDUSTRY FORECAST

OVERALL MARKET FORECAST

   Table: Spain Pharmaceutical Sales Indicators 2008-2016

KEY GROWTH FACTORS - INDUSTRY

   Table: Spain Healthcare Indicators 2008-2016

ECONOMIC ANALYSIS

   Table: Spain - Economic Activity

PRESRIPTION DRUG MARKET FORECAST

   Table: Spain Prescription Drug Sales Indicators 2008-2016

PATENTED DRUG MARKET FORECAST

   Table: Patented Drug Market Indicators 2008-2016

GENERIC DRUG MARKET FORECAST

   Table: Generic Drug Sales Indicators 2008-2016

OTC MEDICINES MARKET FORECAST

   Table: Spain OTC Medicine Sales Indicators 2008-2016

PHARMACEUTICAL TRADE FORECAST

   Table: Table: Exports and Imports Indicators 2008-2016

MEDICAL DEVICE MARKET FORECAST

   Table: Medical Devices Sales Indicators 2008-2016

OTHER HEALTHCARE DATA

KEY RISKS

INDUSTRY RISK REWARD RATINGS

PHARMACEUTICALS RISK/REWARD RATINGS

   Table: Western Europe Pharmaceuticals And Healthcare Risk/Reward Ratings, Q113

MARKET OVERVIEW

INDUSTRY TRENDS AND DEVELOPMENTS

  Epidemiology
  Healthcare Sector
  Research & Development
  Clinical Trials.
  Medical Devices

REGULATORY DEVELOPMENT

  Intellectual Property Issues
  Parallel Trade
  OTC Medicines
  Generic Medicines52
  Pricing Regime
  Reference Pricing System.
  Reimbursement Regime

COMPETITIVE LANDSCAPE

  Pharmaceutical Sector...
  Generic Drug Sector..60
  Biotechnology Sector.62
  Pharmaceutical Retail64

COMPANY PROFILE

ALMIRALL

ESTEVE

GLAXOSMITHKLINE

PFIZER

NOVARTIS

SANOFI

MERCK & CO.

DEMOGRAPHIC FORECAST

   Table: Spain's Population By Age Group, 1990-2020 ('000)
   Table: Spain's Population By Age Group, 1990-2020 (% of total)
   Table: Spain's Key Population Ratios, 1990-2020
   Table: Spain's Rural And Urban Population, 1990-2020

GLOSSARY

METHODOLOGY

METHODOLOGY

  Risk/Reward Ratings Methodology
  Ratings Overview
   Table: Pharmaceutical Business Environment Indicators
  Weighting
   Table: Weighting Of Components
  Sources
Skip to top


The Pharmaceutical Market: Finland US$ 1,295.00 Mar, 2013
The Pharmaceutical Market: France US$ 1,295.00 Jan, 2013 · 107 pages
The Pharmaceutical Market: Germany US$ 1,295.00 Jan, 2013 · 112 pages

Ask Your Question

The Pharmaceutical Market: Spain
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: